Other equities research analysts have also issued research reports about the stock. JPMorgan Chase & Co. reissued an overweight rating on shares of RECKITT BENCKIS/S in a report on Friday, June 26th. Zacks Investment Research raised shares of RECKITT BENCKIS/S from a hold rating to a buy rating and set a $18.00 target price on the stock in a research note on Thursday, May 7th. Morgan Stanley reissued an overweight rating on shares of RECKITT BENCKIS/S in a research report on Monday, June 15th. Credit Suisse Group reaffirmed a neutral rating on shares of RECKITT BENCKIS/S in a report on Wednesday. Finally, UBS Group upgraded RECKITT BENCKIS/S from a neutral rating to a buy rating in a research note on Monday, June 29th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. RECKITT BENCKIS/S has an average rating of Buy and a consensus price target of $18.00.
RBGLY opened at $20.41 on Wednesday. The stock’s 50 day simple moving average is $18.94 and its 200-day simple moving average is $16.93. The company has a current ratio of 0.56, a quick ratio of 0.42 and a debt-to-equity ratio of 0.91. The stock has a market cap of $72.40 billion, a PE ratio of 22.68 and a beta of 0.71. RECKITT BENCKIS/S has a 1 year low of $12.76 and a 1 year high of $21.00.
RECKITT BENCKIS/S Company Profile
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Read More: Options Trading – Understanding Strike Price
Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.